The LLC1 tumour has been well established as a poorly immunogenic tumour with downregulated MHC presentation and an immunosuppressive mMDSC-rich tumour microenvironment.41,53 Cancer vaccine approaches against survivin have been described,36 though due to its self-antigen nature, responses are of low affinity. The gene discussed is BIRC5; the disease is neoplasm.